Graphical abstract. Credit: Cell Reports Medicine (2024). DOI: 10.1016/j.xcrm.2024.101552 Behind the scenes, as tumors progress and gain resistance to treatment, a protein called YB-1 quietly gives directions. Now, researchers at Oregon Health & Science University...
–Supplemental New Drug Application (sNDA) submission based on Phase 3 study of vibegron 75mg (GEMTESA) demonstrating statistically significant reductions in daily micturition and urgency episodes– –If approved, vibegron will be the first and only beta-3 agonist for...
LEXEO Therapeutics, Inc., a clinical stage genetic medicine company, entered an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Under...
CureVac N.V., a global biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), and The University of Texas MD Anderson Cancer Center entered a co-development and licensing agreement to develop novel mRNA-based cancer...
Batavia Biosciences, a contract development and manufacturing organization, has partnered with ChromaTan, Inc. for the development and integration of BioRMB (formerly known as Continuous Countercurrent Tangential Chromatography or CCTC) technology into Batavia’s AAV...
